Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women
Open Access
- 24 October 2012
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 24 (1) , 219-226
Abstract
Summary This study investigated the effects of a single administration of teriparatide on bone turnover markers in postmenopausal women. Teriparatide caused a transient increase in bone resorption and inhibition of bone formation followed by a subsequent increase in bone formation and a decrease in resorption that lasted at least 1 week. Introduction This study aims to investigate the effects of a single subcutaneous administration of teriparatide on bone turnover markers to elucidate why once weekly intermittent administration of teriparatide is effective on osteoporosis. Methods Pharmacokinetics and calcium metabolism and bone turnover parameters were measured in 30 postmenopausal women after two doses of teriparatide (28.2 or 56.5 μg injection) or placebo in a randomized, double-blind, placebo-controlled study. Results Teriparatide plasma concentration increased in a dose-dependent manner, and the maximum concentration was achieved 1 h after injection. Serum levels of calcium and phosphorus were transiently increased and decreased after teriparatide injection, respectively. Calcium metabolism returned to baseline levels 24 h later. Two days after injection, the serum level of 1,25-dihydroxy vitamin D was increased by ~80 % from baseline for both doses of teriparatide. Serum levels of osteocalcin and procollagen type I N-terminal propeptide decreased during the first 24 h followed by a ~10 % increase for 14 days. The serum level of cross-linked N-telopeptide (NTX) of type I collagen increased during the first 24 h followed by a 10 to 12 % dose-dependent suppression from baseline for 14 days. Urinary cross-linked C-telopeptide of type I collagen changes occurred in the same direction as serum NTX, but not dose dependently. Conclusion A single administration of teriparatide caused an immediate, transient increase in bone resorption and inhibited bone formation followed by an increase in bone formation and decrease in resorption for ≥1 week. These findings may provide proof for the effect of a once-weekly regimen of teriparatide on bone turnover.Keywords
This publication has 16 references indexed in Scilit:
- Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture RiskThe Journal of Clinical Endocrinology & Metabolism, 2012
- Changes in vitamin D metabolites during teriparatide treatmentBone, 2012
- Rapid and robust response of biochemical markers of bone formation to teriparatide therapyBone, 2009
- Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with OsteoporosisThe Journal of Clinical Endocrinology & Metabolism, 2009
- The use of parathyroid hormone in the treatment of osteoporosisReviews in Endocrine and Metabolic Disorders, 2006
- Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2001
- Effect of an Intermittent Weekly Dose of Human Parathyroid Hormone (1-34) on Osteoporosis: A Randomized Double-Masked Prospective Study Using Three Dose LevelsOsteoporosis International, 1999
- Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1?34) on rat boneEMC - Cardiologie-Angéiologie, 1995
- Parathyroid Hormone Stimulates the Bone Apposition Rate Independently of Its Resorptive Action: Differential Effects of Intermittent and Continuous Administration*Endocrinology, 1982
- Interpretation of Serum Calcium in Patients with Abnormal Serum ProteinsBMJ, 1973